

**Request for Comments:** Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**Direct Comments to OMB:** Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Merle Myerson, NIH, NHLBI, 6701 Rockledge Drive, MSC 7934, Bethesda, MD 20892-7934, or call non-toll-free number 301-435-0707 or e-mail your request, including your address to: [MyersonM@nhlbi.nih.gov](mailto:MyersonM@nhlbi.nih.gov).

**Comments Due Date:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

Dated: December 11, 2003.

**Peter Savage,**

*Director, DECA, NHLBI, National Institutes of Health.*

[FR Doc. 03-31403 Filed 12-19-03; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Use of Mutants of Human Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) in Treatment of Cancer

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the Food and Drug Administration and the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in International Patent Application PCT/US02/40561, "Use of Mutants of Human Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) in Treatment of Cancer", by Matthew Rechler, filed on December 17, 2002, and claiming priority to U.S. provisional patent application 60/341,920 filed December 17, 2001, to Actis Biologics Inc., which is located in Livermore, California. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to human therapeutics for the treatment of prostate and breast cancers.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 20, 2004 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Brenda J. Hefti, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4632; Facsimile: (301) 402-0220; E-mail: [heftib@od.nih.gov](mailto:heftib@od.nih.gov).

**SUPPLEMENTARY INFORMATION:** In this invention, human IGFBP-1 has been genetically modified so that its affinity for IGF-I and IGF-II is greatly reduced, and it can act only through a novel direct mechanism. These human IGFBP-3 mutants still can inhibit DNA synthesis and stimulate apoptosis, and have been shown to induce apoptosis in human prostate cancer cells. The current invention could selectively exert anti-proliferative action without interfering with IGF actions, and may have therapeutic uses as an anti-tumor agent.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license

would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: December 16, 2003.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 03-31404 Filed 12-19-03; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HOMELAND SECURITY

### Directorate of Science and Technology; Notice of Establishment of Homeland Security Science and Technology Advisory Committee (HSSTAC)

**AGENCY:** Office of the Undersecretary for Science and Technology, Department of Homeland Security.

**ACTION:** Notice.

**SUMMARY:** Section 311 of the Homeland Security Act of 2002, Pub. L. 107-296, established within the Department of Homeland Security the Homeland Security Science and Technology Advisory Committee (HSSTAC). The mission of the HSSTAC is to be a source of independent, scientific and technical planning advice for the Under Secretary for Science and Technology.

**FOR FURTHER INFORMATION CONTACT:** Dr. Ronald Taylor, Director, Office of Studies and Analysis, Department of Homeland Security Science and Technology Directorate, Washington, DC 20528, telephone (202) 205-5041, fax (202) 772-9916.

#### SUPPLEMENTARY INFORMATION:

##### Purpose

The HSSTAC shall make recommendations with respect to the activities of the Under Secretary for Science and Technology, including identifying research areas of potential importance to the security of the Nation. The HSSTAC is to be a source of independent, scientific and technical planning advice for the Under Secretary for Science and Technology.

## Membership

The HSSTAC consists of 20 members appointed by the Under Secretary for Science and Technology. The HSSTAC members are (1) eminent in fields such as emergency response, research, engineering, new product development, business, and management consulting; (2) selected solely on the basis of established records of distinguished service; (3) not employees of the Federal Government; and, (4) selected as to provide representation of a cross-section of the research, development, demonstration, and deployment activities supported by the Under Secretary for Science and Technology.

## Meetings

The HSSTAC will meet at least quarterly at the call of the Chair or whenever one-third of the members so request in writing.

## Duration

The HSSTAC is expected to be needed on a continuing basis. However, the HSSTAC will terminate on November 25, 2005, pursuant to section 311(j) of the Homeland Security Act of 2002 unless extended.

Dated: December 16, 2003.

**Charles E. McQueary,**

*Under Secretary for Science and Technology,  
Department of Homeland Security.*

[FR Doc. 03-31447 Filed 12-19-03; 8:45 am]

BILLING CODE 4410-10-P

## DEPARTMENT OF HOMELAND SECURITY

### Directorate of Science and Technology; Notice of Homeland Security Science and Technology Advisory Committee (HSSTAC) Vacancy and Call for Applications

**AGENCY:** Office of the Undersecretary for Science and Technology, Department of Homeland Security.

**ACTION:** Notice.

**SUMMARY:** Pursuant to section 311 of the Homeland Security Act of 2002, Pub. L. 107-296, the Secretary of the Department of Homeland Security is seeking nominations to fill a vacant seat on the Homeland Security Science and Technology Advisory Committee (HSSTAC). Section 311(b)(1) of the statute requires that the committee include among its membership "Representatives of citizens groups, including economically disadvantaged communities." Therefore, we are requesting qualified individuals that meet this criterion and are interested in serving on this committee to apply for

membership. Nominees should send a letter of interest and brief biography to [hsstac@dhs.gov](mailto:hsstac@dhs.gov) or fax to the attention of Dr. Ron Taylor at 202-772-9916.

Applicants selected for appointment will be required to pass an appropriate security background check prior to appointment to the committee.

**DATES:** Your letter of interest and brief biography should reach the Department of Homeland Security on or before January 15, 2004.

**FOR FURTHER INFORMATION CONTACT:** Dr. Ronald Taylor, Director, Office of Studies and Analysis, Department of Homeland Security Science and Technology Directorate, telephone 202-205-5041, fax 202-772-9916.

## SUPPLEMENTARY INFORMATION:

### Purpose

The HSSTAC shall make recommendations with respect to the activities of the Under Secretary for Science and Technology, including identifying research areas of potential importance to the security of the Nation. The HSSTAC is to be a source of independent, scientific and technical planning advice for the Under Secretary for Science and Technology.

## Membership

The HSSTAC consists of 20 members appointed by the Under Secretary for Science and Technology. The HSSTAC also includes emergency first-responders or representatives of organizations or associations of emergency first-responders. (We are not requesting applicants for these positions in this notice.) The HSSTAC also includes representatives of citizens groups, including economically-disadvantaged communities. The HSSTAC members are (1) eminent in fields such as emergency response, research, engineering, new product development, business, and management consulting; (2) selected solely on the basis of established records of distinguished service; (3) not employees of the Federal Government; and, (4) selected as to provide representation of a cross-section of the research, development, demonstration, and deployment activities supported by the Under Secretary for Science and Technology.

Members will serve terms of office of 3 years. However, to permit orderly turnover of the committee's membership, the original members of the HSSTAC will be appointed to three groups of approximately equal numbers each, and their terms of office will be staggered. One group will have a term

of 1 year, 1 a term of 2 years, and the other a term of 3 years.

While attending meetings or otherwise engaged in Committee business, Committee members are authorized travel and subsistence or *per diem* allowances (as appropriate) in accordance with Federal government regulations.

## Meetings

The HSSTAC will meet at least quarterly at the call of the Chair or whenever one-third of the members so request in writing.

## Duration

The HSSTAC is expected to be needed on a continuing basis. However, the HSSTAC will terminate on November 25, 2005, pursuant to section 311(j) of the Homeland Security Act of 2002 unless extended.

Dated: December 16, 2003.

**Charles E. McQueary,**

*Under Secretary for Science and Technology,  
Department of Homeland Security.*

[FR Doc. 03-31448 Filed 12-19-03; 8:45 am]

BILLING CODE 4410-10-P

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[USCG-2003-16728]

**Maritime Security Directives (MARSEC Directives) 104-1, 104-2, 104-3, 104-4, 105-1, 105-2, 105-3 and 106-1; Performance Standards for Cruise Ships and Facilities, Passenger Vessels/Ferryboats and Facilities, Cargo/Other Commercial Vessels and Facilities, Mobile Oil Drilling Units/Off-Shore Supply Vessels, and Outer Continental Shelf (OCS) Facilities**

**AGENCY:** Coast Guard, DHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Coast Guard announces the availability of MARSEC Directives 104-01, 104-02, 104-03, 104-4, 105-01, 105-02, 105-03, and 106-1. The MARSEC Directives provide performance standards to assist facility and vessel owners/operators with developing facility and vessel security plans that comport with national maritime security initiatives. Information within the MARSEC Directives is designated sensitive security information (SSI) and is not subject to public release.

**DATES:** The MARSEC Directives listed above will be available on December 22, 2003.